Research Article
OLFML2A Overexpression Predicts an Unfavorable Prognosis in Patients with AML
Table 1
Association analysis between OLFML2A expression levels and clinicopathologic features in the TCGA-AML database.
| Characteristic | Low expression of OLFML2A | High expression of OLFML2A | value |
| n | 75 | 76 | | Gender, n (%) | | | 1.000 | Female | 34 (22.5%) | 34 (22.5%) | | Male | 41 (27.2%) | 42 (27.8%) | | Race, n (%) | | | 1.000 | Asian | 0 (0%) | 1 (0.7%) | | Black or African American | 6 (4%) | 7 (4.7%) | | White | 67 (45%) | 68 (45.6%) | | Age, n (%) | | | 0.211 | ≤60 | 48 (31.8%) | 40 (26.5%) | | >60 | 27 (17.9%) | 36 (23.8%) | | WBC count (×109/L), n (%) | | | 0.191 | ≤20 | 43 (28.7%) | 34 (22.7%) | | >20 | 32 (21.3%) | 41 (27.3%) | | BM blasts (%), n (%) | | | 0.444 | ≤20 | 27 (17.9%) | 33 (21.9%) | | >20 | 48 (31.8%) | 43 (28.5%) | | PB blasts (%), n (%) | | | 0.372 | ≤70 | 39 (25.8%) | 33 (21.9%) | | >70 | 36 (23.8%) | 43 (28.5%) | | Cytogenetic risk, n (%) | | | 0.035 | Favorable | 21 (14.1%) | 10 (6.7%) | | Intermediate | 40 (26.8%) | 42 (28.2%) | | Poor | 13 (8.7%) | 23 (15.4%) | | FAB classifications, n (%) | | | 0.278 | M0 | 6 (4%) | 9 (6%) | | M1 | 17 (11.3%) | 18 (12%) | | M2 | 23 (15.3%) | 15 (10%) | | M3 | 7 (4.7%) | 8 (5.3%) | | M4 | 14 (9.3%) | 15 (10%) | | M5 | 4 (2.7%) | 11 (7.3%) | | M6 | 2 (1.3%) | 0 (0%) | | M7 | 1 (0.7%) | 0 (0%) | | Cytogenetics, n (%) | | | 0.014 | Normal | 32 (23.7%) | 37 (27.4%) | | +8 | 7 (5.2%) | 1 (0.7%) | | Del (5) | 0 (0%) | 1 (0.7%) | | Del (7) | 3 (2.2%) | 3 (2.2%) | | Inv (16) | 8 (5.9%) | 0 (0%) | | t (15; 17) | 5 (3.7%) | 6 (4.4%) | | t (8; 21) | 4 (3%) | 3 (2.2%) | | t (9; 11) | 0 (0%) | 1 (0.7%) | | Complex | 7 (5.2%) | 17 (12.6%) | | FLT3 mutation, n (%) | | | 0.005 | Negative | 59 (40.1%) | 43 (29.3%) | | Positive | 14 (9.5%) | 31 (21.1%) | | IDH1 R132 mutation, n (%) | | | 0.579 | Negative | 67 (45%) | 69 (46.3%) | | Positive | 8 (5.4%) | 5 (3.4%) | | IDH1 R172 mutation, n (%) | | | 0.245 | Negative | 72 (48.3%) | 75 (50.3%) | | Positive | 2 (1.3%) | 0 (0%) | | IDH1 R140 mutation, n (%) | | | 0.745 | Negative | 67 (45%) | 70 (47%) | | Positive | 7 (4.7%) | 5 (3.4%) | | RAS mutation, n (%) | | | 1.000 | Negative | 71 (47.3%) | 71 (47.3%) | | Positive | 4 (2.7%) | 4 (2.7%) | | NPM1 mutation, n (%) | | | 1.000 | Negative | 59 (39.3%) | 58 (38.7%) | | Positive | 16 (10.7%) | 17 (11.3%) | |
|
|